FGL1 also acts as a tumor suppressor in HCC through protein kinase B/mammalian target of rapamycin (Akt/mTOR) signaling 33, a critical pathway in the development and progression of HCC 35. Here, FGL1 is linked to hepatocellular carcinoma.